Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 10:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 293 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Herpes Clear all
Recruiting Phase 4 Interventional

Safety of the Herpes Zoster Subunit Vaccine in Lupus

NCT05559671
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Herpes Zoster Subunit (HZ/su) Vaccine, Placebo
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New York, New York • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 4 Interventional

A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons

NCT00161434
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
valacyclovir, placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Oct 10, 2026, 10:20 AM EDT
Terminated No phase listed Observational

Solid Organ Transplant SHINGRIX

NCT03993717
View directory record Official record
Conditions
Kidney Transplant; Complications
Interventions
SHINGRIX
Biological
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 10, 2026, 10:20 AM EDT
Terminated Phase 3 Interventional

A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia

NCT02412917
View directory record Official record
Conditions
Shingles, Herpes Zoster, Postherpetic Neuralgia
Interventions
FV-100, valacyclovir
Drug
Lead sponsor
ContraVir Pharmaceuticals, Inc.
Industry
Eligibility
30 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 10, 2026, 10:20 AM EDT
Completed No phase listed Observational

A Two Arm, Multi-Site Clinical Evaluation of the ARIES HSV 1&2 Assay in Symptomatic Patients

NCT02092233
View directory record Official record
Conditions
Herpes
Interventions
Not listed
Lead sponsor
Luminex Corporation
Industry
Eligibility
Not listed
Enrollment
1,963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
3
States / cities
Springfield, Massachusetts • Albuquerque, New Mexico • Burlington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Abreva in the Suppression of Herpes Simplex Virus Eruptions

NCT06558838
View directory record Official record
Conditions
Herpes Simplex Oral
Interventions
acyclovir-penciclovir cream, Abreva
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 10, 2026, 10:20 AM EDT
Not listed Phase 2 Interventional

Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

NCT00005025
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
herpes simplex thymidine kinase, ganciclovir
Biological · Drug
Lead sponsor
John Stoddard Cancer Center at Iowa Methodist Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates

NCT01519570
View directory record Official record
Conditions
Herpes Zoster Disease
Interventions
An informational packet regarding shingles and the HZV was sent to patients identified by the EMR
Other
Lead sponsor
Ohio State University
Other
Eligibility
60 Years and older
Enrollment
2,589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

NCT05047770
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su, Flu D-QIV, mRNA-1273
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
46
States / cities
Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 2 Interventional

The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

NCT03604406
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
Interventions
Varicella Zoster Vaccine, Placebo Injection
Biological · Other
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
5
States / cities
Boise, Idaho • Eagan, Minnesota • Clovis, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 10, 2026, 10:20 AM EDT
Terminated Phase 1 Interventional

Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery

NCT02031965
View directory record Official record
Conditions
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma
Interventions
oncolytic HSV-1716, dexamethasone, therapeutic conventional surgery, laboratory biomarker analysis
Biological · Drug · Procedure + 1 more
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
12 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2016 · Synced Oct 10, 2026, 10:20 AM EDT
Withdrawn No phase listed Observational

NOWDx Test for the Diagnosis of Herpes Simplex Virus Type 2

NCT04294030
View directory record Official record
Conditions
HSV-2 Infection, Herpes Simplex Virus Infection
Interventions
Diagnostic Test: NOWDx HSV-2 Test
Device
Lead sponsor
NOWDiagnostics, Inc.
Industry
Eligibility
18 Years to 64 Years
Timeline
2023
U.S. locations
3
States / cities
Tempe, Arizona • Coral Gables, Florida • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 10, 2026, 10:20 AM EDT
Completed No phase listed Observational

Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States

NCT00026728
View directory record Official record
Conditions
Kaposi's Sarcoma, Herpesviridae Infection
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
20,169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 10, 2026, 10:20 AM EDT
Completed No phase listed Observational

Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity

NCT02910284
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
Observational
Biological
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Clinical Study for the Treatment of Cold Sore

NCT00769314
View directory record Official record
Conditions
Herpes Labialis
Interventions
Acyclovir Lauriad, Placebo
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 3 Interventional

Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

NCT00209352
View directory record Official record
Conditions
VZV Infection After Bone Marrow Transplantation
Interventions
Acyclovir
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 10, 2026, 10:20 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

NCT05432583
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
BNT163, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
6
States / cities
Tempe, Arizona • Chicago, Illinois • Raleigh, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 2 Interventional

A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes

NCT00486200
View directory record Official record
Conditions
Herpes Genitalis
Interventions
ASP2151, valacyclovir, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Not applicable Interventional

A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients

NCT00002084
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
46
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Herpes Simplex Type 1 Suppression in Hepatitis C

NCT01580995
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis

NCT00453401
View directory record Official record
Conditions
Herpes Labialis
Interventions
NB-001
Drug
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
28
States / cities
Huntsville, Alabama • Anaheim, California • Westlake Village, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 30, 2008 · Synced Oct 10, 2026, 10:20 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

NCT05703607
View directory record Official record
Conditions
Shingles, Herpes Zoster Infection, Human
Interventions
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection, Candidate 3: PF-07921186: VZV modRNA Suspension for Injection, Shingrix, Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
35
States / cities
Gilbert, Arizona • Mesa, Arizona • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Results available

Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes

NCT02871492
View directory record Official record
Conditions
Herpes Labialis
Interventions
Pritelivir 5% w/w ointment, Pritelivir ointment matching placebo, Zovirax® cream
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Santa Rosa, California • Pinellas Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 10, 2026, 10:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VivaGel™ in Healthy Young Women

NCT00331032
View directory record Official record
Conditions
Herpes Simplex II
Interventions
3% w/w SPL7013 Gel, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 24 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 10, 2026, 10:20 AM EDT